• Vitreoretinal surgeon at St. Michael’s Hospital, The Hospital for Sick Children and Kensington Eye Institute
• Associate Professor and Chair of Clinical Research in the Department of Ophthalmology and Vision Sciences, University of Toronto
• 150+ peer-reviewed publications in top academic journals
• MD, McMaster University; pediatric vitreoretinal surgery fellowship, University of Southern California; M.A. clinical epidemiology, Harvard School of Public Health

• Distinguished business leader with extensive experience in corporate finance, private equity and venture capital
• Senior management and board of director roles at biotech, financial services and real estate companies
• Former co-founder and Executive Chairman of a radiotherapeutic company
• Chairman of the Board of Verity Pharmaceuticals, a Canadian privately owned and operated specialty pharmaceutical company

• Medical Retina Specialist and Cataract surgeon, Sunnybrook Health Sciences Centre
• Assistant Professor, Department of Ophthalmology & Vision Sciences, University of Toronto• Expertise: Diagnosis and management of inherited retinal diseases
• PhD, York University; MD, McMaster University; Medical Retina fellow, Moorfields Eye Hospital, UK

• 26+ years creating and commercializing new medical devices
• Senior business and engineering roles developing and introducing new medical devices in neurotechnology, ophthalmology, surgical navigation, imaging and optics
• Business strategy and execution oversight for market analysis, product roadmap and definition, intellectual property, health economics and reimbursement, regulatory affairs, business development, and market introduction
• Electrical and biomedical engineering degrees, University of Toronto; Licensed Professional Engineer

• Founder and CEO of Rosenblatt Life Science Consultants
• 30+ years assisting pharmaceutical companies with financial forecasting, opportunities assessment and business valuations
• Former Head of the Global Forecasting & Opportunity Assessment consulting group, IMS Health (now IQVIA)
• MBA and PhD, marketing science, Concordia University; PMSA Lifetime Achievement Award

• Chair and professor, Department of Ophthalmology and Visual Sciences, University of Utah
• Senior clinical, educational and innovation roles at the Prism Eye Institute; University of Toronto; Trillium Health Hospital Network; Center for Glaucoma Innovation, University of Utah
• One of the leading complex eye surgeons globally
• Designed various instruments and implants for cataract, iris reconstruction, and glaucoma surgeries•Consultant to manufacturers developing new medical devices and technologies
• MD, University of Toronto

•Professor of Engineering at the Massachusetts Institute of Technology (MIT)•Precision machine design class has generated research ideas and collaborations. Projects received subsequent funding to assist in accelerating prototypes for new medical devices•Design efforts have yielded over 7 dozen patents and numerous design awards•PhD, Mechanical Engineering, MIT; Fellow, American Society of Mechanical Engineers

B.S. in Mechanical Engineering and Physics, M.S. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT). PhD candidate in Mechanical Engineering department with a focus in Mechanical Design.

Drug, device, and combination product expert with 25 years of experience leading R&D teams, resulting in 3 ophthalmic drug approvals
•Extensive expertise with strategy, planning and executing all stages of drug development that targets ocular diseases, including working with clinical, regulatory, scientific, non-clinical, and technical and product development areas
•Senior leadership experience with biotechnology and pharmaceutical companies, including PYC Therapeutics, BridgeBio Pharma, Clearside Biomedical and Alcon (formerly a subsidiary of Novartis)
•PhD, Loyola University Chicago; Post-doctoral research, University of California, Irvine.